Skip to main content
. Author manuscript; available in PMC: 2022 Oct 6.
Published in final edited form as: Cell Metab. 2022 May 10;34(6):805–817. doi: 10.1016/j.cmet.2022.04.010

Figure 5. Potential clinical niche for a β-blocker for the primary prevention of osteoporosis.

Figure 5.

Although the established osteoporosis drugs (bisphosphonates, denosumab, teriparatide, abaloparatide, and Romosozumab) are prescribed for the treatment of established osteoporosis, following the results of the Women’s Health Initiative, there is virtually no viable option for the primary prevention of osteoporosis. β-blockers could potentially fill this niche.